ScreenerHero

OKUR OnKure Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · onkuretherapeutics.com
2.300USD-2.13%Mkt Cap: 92.91M $P/E: —

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead pr…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap92.91M USD
Enterprise Value-75.84M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-59.52M USD
Revenue/Share—
Last Price2.300 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees45
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.61
PEG—
EV/EBITDA1.23
EV/Revenue—
P/S—
P/B0.58
EPS (TTM)-2.84
EPS (Forward)-1.53
52W Range
2.1305% of range5.380
52W High5.380 USD
52W Low2.130 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-105.93%
ROA-95.81%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-51.83M USD
CapEx (TTM)46.00K USD
FCF Margin—
FCF Yield-29.18%
Net Debt-175.46M USD
Net Debt/EBITDA2.84
Balance Sheet
Debt/Equity0.01
Current Ratio26.75
Quick Ratio26.55
Book Value/Sh4.25 USD
Cash/Share4.36 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateOct 7, 2024
Analyst Consensus
Rating—
Target (Mean)15.50 USD
Upside (mean)+573.9%
Target Range11.00 USD – 21.00 USD
11.00+573.9% to mean21.00
# Analysts4
Ownership
Shares Out.40.40M
Float21.38M
Insiders10.17%
Institutions86.75%
Short Interest
Short Ratio8.4d
Short % Float3.78%
Short % Out.3.40%
Shares Short1.38M
Short (prev mo.)1.07M
Technical
SMA 503.525 (-34.7%)
SMA 2003.663 (-37.2%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)319.35K
Avg Vol (10d)544.03K
Technical Indicators
RSI (14)22.4
MACD-0.3351
MACD Signal-0.3126
MACD Hist.-0.0225
BB Upper3.483 USD
BB Middle2.841 USD
BB Lower2.199 USD
BB Width45.20%
ATR (14)0.2550 USD
Vol Ratio (20d)1.44x